Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 4130722)

Published in Cancer Biol Ther on July 21, 2014

Authors

Adam Kittai1, Mariam Meshikhes2, Jeanny B Aragon-Ching3

Author Affiliations

1: Department of Internal Medicine; George Washington University Medical Center; Washington, DC USA.
2: Department of International Medicine Programs; George Washington University; Washington, DC USA.
3: Division of Hematology/Oncology; Department of Medicine; George Washington University Medical Center; Washington, DC USA.

Associated clinical trials:

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810

Articles citing this

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev (2016) 0.76